Granzyme B Imaging Compounds for Immunotherapy Response Assessment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current imaging technologies struggle to effectively assess patient response to cancer immunotherapy, as they often rely on anatomic imaging and FDG-PET, which do not accurately reflect Granzyme B expression, a downstream marker of cytotoxic T-cell activity, leading to challenges in determining therapeutic efficacy.
Innovation Solution
Development of specific compounds, such as Formula (I) and Formula (II), which exhibit high binding affinity to Granzyme B, enabling effective imaging and therapeutic applications by targeting this biomarker.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional imaging methods (anatomic imaging and FDG-PET) are used to assess patient response to cancer immunotherapy, then the imaging can be performed with existing technologies, but the imaging does not accurately reflect Granzyme B expression and therapeutic efficacy
Solution Approach 1:
The patent changes the molecular target parameter from non-specific metabolic markers (FDG) to Granzyme B-specific markers. By designing compounds that specifically bind to Granzyme B with high affinity, the measurement precision of immunotherapy response is improved while using standard PET imaging technology, thus not increasing device complexity
Solution Approach 2:
The patent introduces Granzyme B-specific imaging compounds as intermediaries between the imaging system and the biological target. These compounds act as mediators that specifically bind to Granzyme B, enabling accurate detection of immunotherapy response without requiring complex new imaging equipment
2Measurement precision
If Granzyme B-specific imaging compounds are developed to accurately assess immunotherapy response, then measurement precision is improved, but the complexity of compound development and validation increases
Solution Approach 1:
The patent designs imaging compounds with universal applicability across different immunotherapy types. The Granzyme B-specific compounds can assess response to various immunotherapies (checkpoint inhibitors, CAR-T, etc.), reducing the need for multiple specialized compounds and simplifying the development process
Solution Approach 2:
The patent performs preliminary validation of Granzyme B as a biomarker before developing clinical imaging protocols. By establishing Granzyme B's correlation with immunotherapy response in preclinical models first, the path to clinical application is simplified and systematic complexity is reduced
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds allow for precise identification of patients responsive to immunotherapeutic agents and provide therapeutic benefits by directly imaging Granzyme B, overcoming the limitations of conventional imaging methods.
Implementation Method 1
A is a chelating moiety chelating the metal
Data Source
AI summary
Compounds of Formula (I) and Formula (II), which are capable of binding to granzyme B. Also provided herein are pharmaceutical compositions comprising such for use in, for example, imaging Granzyme B and/or treating immunoregulatory abnormalities.